Veloxis Pharmaceuticals & Athena Drug Delivery Solutions Announce Partnership
Veloxis Pharmaceuticals and Athena Drug Delivery Solutions recently announced an alliance in which Athena will obtain exclusive rights in certain emerging market territories to manufacture and, with third parties, develop, register, and commercialize Veloxis’ AtorFen (Fenofibrate Atorvastatin fixed-dose combination).
AtorFen will contain the lowest fully effective dose of fenofibrate and is a combination of two effective dyslipidemia treatments in one tablet, thereby potentially improving patient compliance. The product has been developed by Veloxis through Phase II in the
Results showed significant improvements in HDL-C, triglycerides, VLDL, and fibrinogen compared with atorvastatin alone (Lipitor 40 mg) as well as significantly greater effect on non-HDL-C, LDL-C, triglycerides, and total cholesterol compared with fenofibrate alone (Tricor 145 mg).
Under this alliance, Athena will establish and fund AtorFen manufacturing capabilities in
“This alliance will enable Veloxis to establish a competitive presence for AtorFen in emerging markets,” said William Polvino, MD, Chief Executive Officer of Veloxis. “Substantial future growth in the pharmaceutical industry is expected to come from this region where cardiovascular morbidity is on the rise. We’re delighted to have the opportunity to work with Athena, a company that is well positioned in emerging markets. This agreement is part of our strategy to out-license our cardiovascular portfolio to partners who can realize the full value of these assets.”
Based in
Total Page Views: 1039
